Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01054599 : Does Memantine Improve Verbal Memory Task Performance in Subjects With Partial Epilepsy and Memory Dysfunction?
PhaseN/A
AgesMin: 18 Years Max: 65 Years
Eligibility
Inclusion Criteria:

- 18-65 years of age

- Normal IQ as estimated by the Wechsler Test of Adult Reading (WTAR)

- Able to give consent

- Able to live independently and complete activities of daily living

- Stable frequency of seizures. There is no minimum/maximum criteria for the frequency
of partial seizures. Those with infrequent secondary generalized seizures may
participate, with infrequent seizures defined as two or fewer per year.

- The subject's treating physician does not believe a change in anticonvulsant regimen
to be warranted. The anticonvulsant drugs must remain unchanged during the 26 week
trial.

- Partial-onset seizures. Seizure type will be determined by clinical history, MRI,
SPECT and/or PET imaging, and interictal and/or ictal EEG.

- Either symptomatic or idiopathic seizures.

Exclusion Criteria:

- Non-epileptic seizures

- Prior surgical resection for treatment of seizures

- Progressive neurologic illness (i.e. tumor evident on MRI)

- Current alcohol or drug abuse, as this may affect memory by other mechanisms. This
information may be obtained by self-report, from the referring physician or by
medical record.

- Diagnosis of Alzheimer's disease, nutritional deficiency, infection or
metabolic/electrolyte disorder causing memory loss.

- Non-native English speaking and/or multilingual.

- Seizure(s) must not have occurred within 3 days of testing.

- Subjects who are pregnant will not be eligible to take part in the study, as
memantine is classified as a Pregnancy Category B drug and may pose risk to the
fetus.

- Women who are breastfeeding may not participate in this study.

- Those with renal tubular acidosis or infections of the urinary tract will not be
eligible for participation, as memantine is renally cleared and conditions that
alkalinize the urine may reduce clearance of the drug.

- Subjects with severe renal impairment, defined as a creatinine clearance of ?29
mL/min, will be excluded as such patients may not tolerate the proposed dosing
schedule.
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT01054599      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740